Cladribine as a therapeutic option in multiple sclerosis

被引：10

作者：

Warnke, Clemens ^{[1
]}

Leussink, Verena I. ^{[1
]}

Goebels, Norbert ^{[1
]}

Aktas, Orhan ^{[1
]}

Boyko, Alexey ^{[2
,3
]}

Kieseier, Bernd C. ^{[1
]}

Hartung, Hans-Peter ^{[1
]}

机构：

[1] Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany

[2] Russian State Med Univ, Dept Neurol & Neurosurg, Moscow 117437, Russia

[3] Moscow MS Ctr, Moscow, Russia

来源：

CLINICAL IMMUNOLOGY | 2012年 / 142卷 / 01期

关键词：

Cladribine; Multiple sclerosis; Immunosuppressant; Oral drugs; DOUBLE-BLIND; 2-CHLORODEOXYADENOSINE; TOXICITY; 2-CHLORO-2'-DEOXYADENOSINE; APOPTOSIS; TABLETS; SAFETY; CELLS; TRIAL;

D O I：

10.1016/j.clim.2011.05.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug. (C) 2011 Published by Elsevier Inc.

引用

页码：68 / 75

页数：8

共 50 条

[21] Pregnancy outcomes with cladribine in multiple sclerosis
Reactions Weekly, 2020, 1807 (1) : 9 - 9
[22] Treating multiple sclerosis with generic cladribine
Alvarez-Gonzalez, C.
Allen-Philbey, K.
Mathews, J.
Espasandin, M.
Turner, B. P.
Gnanapavan, S.
Marta, M.
Giovannoni, G.
Baker, D.
Schmierer, K.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 604 - 605
[23] CLADRIBINE TREATMENT OF MULTIPLE-SCLEROSIS
REILLY, D
LANCET, 1994, 344 (8921): : 537 - 537
[24] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
Cook, S.
Vermersch, P.
Comi, G.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. Soelberg
Hamlett, A.
Miret, M.
Weiner, J.
Viglietta, V.
Musch, B.
Greenberg, S. J.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
[25] FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis
Klatt, J.
Hartung, H.-P.
Hohlfeld, R.
NERVENARZT, 2007, 78 (10): : 1200 - 1207
[26] Multiple sclerosis: Orally administered cladribine displays efficacy in multiple sclerosis trial
Yates D.
Nature Reviews Neurology, 2010, 6 (4) : 182 - 182
[27] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Savic, Radojka M.
Novakovic, Ana M.
Ekblom, Marianne
Munafo, Alain
Karlsson, Mats O.
CLINICAL PHARMACOKINETICS, 2017, 56 (10) : 1245 - 1253
[28] Cladribine to Treat Relapsing Forms of Multiple Sclerosis
Giovannoni, Gavin
NEUROTHERAPEUTICS, 2017, 14 (04) : 874 - 887
[29] Development of oral cladribine for the treatment of multiple sclerosis
Hartung, Hans-Peter
Aktas, Orhan
Kieseier, Bernd
Comi, Giancarlo
JOURNAL OF NEUROLOGY, 2010, 257 (02) : 163 - 170
[30] Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Radojka M. Savic
Ana M. Novakovic
Marianne Ekblom
Alain Munafo
Mats O. Karlsson
Clinical Pharmacokinetics, 2017, 56 : 1245 - 1253

← 1 2 3 4 5 →